ArticleHeart rhythm O22025
Association between dementia and left atrial appendage occlusion in patients with atrial fibrillation: A TriNetX-based retrospective cohort study with target trial emulation.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of Osteoarthritis and Arthroplasty Between Baclofen and Tizanidine: A Target Trial Emulation Study.Clinical drug investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia linked to an elevated risk of stroke and dementia. Emerging observational evidence suggests that left atrial appendage occlusion (LAAO) may reduce the risk of dementia in patients with AF; however, further research is required to confirm this potential benefit. Objective: This study aimed to compare the effectiveness of LAAO vs direct oral anticoagulants (DOACs) in reducing the risk of dementia in patients with AF. Methods: We conducted target trial emulation using data from the TriNetX research network. Patients with AF were allocated to 2 cohorts (2270 patients in each one), treated either with LAAO or with DOACs, and balanced with propensity score matching. The primary end points were composite dementia, vascular dementia, and Alzheimer disease. Secondary end points included mortality, ischemic stroke, intracranial hemorrhage, and major adverse cardiovascular events. Follow-up was conducted over 3 years. Results: At 3-year follow-up, the risk of composite dementia was lower in the LAAO group than in the DOAC group (hazard ratio 0.57; 95% confidence interval 0.38-0.85). Subgroup analyses demonstrated consistent results, favoring the LAAO group. No significant differences were observed in the incidence of secondary outcomes. Conclusion: This real-world study suggests that LAAO is associated with a lower risk of dementia in patients with AF compared with DOACs. Further prospective research with long-term follow-up is needed to validate our findings in the population with AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.